Cover Image
市場調查報告書

癌症疼痛:開發平台分析

Cancer Pain - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192514
出版日期 內容資訊 英文 157 Pages
訂單完成後即時交付
價格
Back to Top
癌症疼痛:開發平台分析 Cancer Pain - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 157 Pages
簡介

所謂癌症疼痛定義是指癌症對人體造成損傷,人體對這個損傷的各種反應之複雜組成的感覺。腫瘤對人體造成壓迫或侵蝕、為了治療、診斷所做的處置、反疫反應或荷爾蒙釋出造成皮膚、神經等病變而引發疼痛。可使用止痛劑療法或Opioids(類鴉片物質)止痛藥、佐劑(佐藥)、心理治療、麻醉學·神經外科性疼痛管理手法等,來治療癌症疼痛。

本報告提供全球各國治療癌症疼痛所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

癌症疼痛概要

治療藥的開發

  • 癌症疼痛開發中產品:概要
  • 癌症疼痛開發中產品:比較分析

各企業開發中的癌症疼痛治療藥

大學/研究機關研究中的癌症疼痛治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

癌症疼痛治療藥:開發中的產品一覽(各企業)

癌症疼痛治療藥:研究中的產品一覽(各大學/研究機關)

癌症疼痛治療藥的開發企業

  • AngioChem Inc.
  • Aphios Corporation
  • AstraZeneca Plc
  • BCN Peptides, S.A.
  • Benitec Biopharma Limited
  • BioDelivery Sciences International, Inc.
  • ChironWells GmbH
  • Daewoong Pharmaceutical Co., Ltd.
  • 第一三共
  • 爬蔓植物製藥
  • Grunenthal GmbH
  • GW Pharmaceuticals Plc
  • 久光製藥
  • Immupharma Plc
  • IntelGenx Corp.
  • Kineta, Inc.
  • Kolon Life Science, Inc.
  • Neurocentrx Pharma Ltd.
  • 日本化藥
  • Orion Oyj
  • Pain Therapeutics, Inc.
  • Pfizer Inc.
  • Pharmaleads SA
  • Recordati S.p.A.
  • Ribomic Inc.
  • Trillium Therapeutics Inc.
  • Virobay Inc.
  • WEX Pharmaceuticals Inc.
  • Zynerba Pharmaceuticals, Inc.

癌症疼痛:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

癌症疼痛治療藥:開發中產品的最新趨勢

癌症疼痛治療藥:暫停開發的產品

癌症疼痛治療藥:中止開發的產品

癌症疼痛相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8691IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Pipeline Review, H2 2016, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.

Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 8, 5, 3, 19, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.Cancer Pain.

Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Cancer Pain Overview 8
  • Therapeutics Development 9
  • Pipeline Products for Cancer Pain - Overview 9
  • Pipeline Products for Cancer Pain - Comparative Analysis 10
  • Cancer Pain - Therapeutics under Development by Companies 11
  • Cancer Pain - Therapeutics under Investigation by Universities/Institutes 13
  • Cancer Pain - Pipeline Products Glance 14
  • Late Stage Products 14
  • Clinical Stage Products 15
  • Early Stage Products 16
  • Unknown Stage Products 17
  • Cancer Pain - Products under Development by Companies 18
  • Cancer Pain - Products under Investigation by Universities/Institutes 21
  • Cancer Pain - Companies Involved in Therapeutics Development 22
  • Alexza Pharmaceuticals Inc 22
  • AngioChem Inc 23
  • Aoxing Pharmaceutical Company Inc 24
  • Aphios Corp 25
  • AstraZeneca Plc 26
  • Benitec Biopharma Ltd 27
  • BioDelivery Sciences International Inc 28
  • ChironWells GmbH 29
  • Colby Pharmaceutical Company 30
  • Daiichi Sankyo Company Ltd 31
  • Dompe Farmaceutici SpA 32
  • Fujimoto Pharmaceutical Corp 33
  • Grunenthal GmbH 34
  • GW Pharmaceuticals Plc 35
  • Hisamitsu Pharmaceutical Co Inc 36
  • Immupharma Plc 37
  • IntelGenx Corp 38
  • iX Biopharma Ltd 39
  • Kancera AB 40
  • Klaria Pharma Holding AB 41
  • Komipharm International Co Ltd 42
  • KPI Therapeutics Inc 43
  • Neurocentrx Pharma Ltd 44
  • Nippon Kayaku Co Ltd 45
  • Orion Oyj 46
  • Pain Therapeutics Inc 47
  • Pfizer Inc 48
  • Pharmaleads SA 49
  • Recordati SpA 50
  • Ribomic Inc. 51
  • Trillium Therapeutics Inc 52
  • Virobay Inc 53
  • WEX Pharmaceuticals Inc 54
  • Zynerba Pharmaceuticals Inc 55
  • Cancer Pain - Therapeutics Assessment 56
  • Assessment by Monotherapy Products 56
  • Assessment by Target 57
  • Assessment by Mechanism of Action 60
  • Assessment by Route of Administration 63
  • Assessment by Molecule Type 65
  • Drug Profiles 67
  • ANG-2002 - Drug Profile 67
  • AQU-118 - Drug Profile 68
  • AZD-8797 - Drug Profile 69
  • BBI-11008 - Drug Profile 71
  • buprenorphine hydrochloride - Drug Profile 72
  • cebranopadol - Drug Profile 73
  • CPC-111 - Drug Profile 76
  • crotalphine - Drug Profile 77
  • CSTI-200 - Drug Profile 78
  • dexmedetomidine hydrochloride - Drug Profile 79
  • dronabinol - Drug Profile 81
  • Drug 1 for Migraine and Cancer Pain - Drug Profile 82
  • Drug 2 for Migraine and Cancer Pain - Drug Profile 83
  • Drug 3 for Migraine and Cancer Pain - Drug Profile 84
  • Drug for Cancer Neuropathic Pain - Drug Profile 85
  • Drug for Migraine and Cancer Pain - Drug Profile 86
  • fentanyl - Drug Profile 87
  • fentanyl citrate - Drug Profile 88
  • fentanyl citrate - Drug Profile 90
  • fentanyl citrate - Drug Profile 91
  • fentanyl citrate ER - Drug Profile 92
  • gabapentin - Drug Profile 93
  • HP-3150 - Drug Profile 94
  • HS-198 - Drug Profile 95
  • hydromorphone hydrochloride - Drug Profile 96
  • HYLP-002 - Drug Profile 97
  • INT-0010 - Drug Profile 98
  • IPP-102199 - Drug Profile 99
  • methadone hydrochloride - Drug Profile 100
  • nabiximols - Drug Profile 101
  • Nervarna - Drug Profile 108
  • PAX-1 - Drug Profile 109
  • Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain, Fibromyalgia, Inflammatory Pain and Neuropathic Pain - Drug Profile 110
  • Peptide to Target CANP for Cardiovasclar and Cancer Pain - Drug Profile 111
  • PL-265 - Drug Profile 112
  • QX-314 - Drug Profile 113
  • RBM-004 - Drug Profile 114
  • RBM-007 - Drug Profile 115
  • resiniferatoxin - Drug Profile 116
  • saracatinib difumarate - Drug Profile 118
  • Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 120
  • Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 121
  • Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 122
  • Small Molecules for Pancreatic Cancer and Perineural Invasion - Drug Profile 123
  • tanezumab - Drug Profile 124
  • Tetrodotoxin - Drug Profile 127
  • tilidine hydrochloride - Drug Profile 129
  • U-2902 - Drug Profile 130
  • VBY-825 - Drug Profile 132
  • zucapsaicin - Drug Profile 133
  • ZYN-001 - Drug Profile 135
  • Cancer Pain - Dormant Projects 137
  • Cancer Pain - Discontinued Products 141
  • Cancer Pain - Product Development Milestones 142
  • Featured News & Press Releases 142
  • Appendix 152
  • Methodology 152
  • Coverage 152
  • Secondary Research 152
  • Primary Research 152
  • Expert Panel Validation 152
  • Contact Us 152
  • Disclaimer 153

List of Tables

  • Number of Products under Development for Cancer Pain, H2 2016 13
  • Number of Products under Development for Cancer Pain - Comparative Analysis, H2 2016 14
  • Number of Products under Development by Companies, H2 2016 15
  • Number of Products under Development by Companies, H2 2016 (Contd..1) 16
  • Number of Products under Investigation by Universities/Institutes, H2 2016 17
  • Comparative Analysis by Late Stage Development, H2 2016 18
  • Comparative Analysis by Clinical Stage Development, H2 2016 19
  • Comparative Analysis by Early Stage Development, H2 2016 20
  • Comparative Analysis by Unknown Stage Development, H2 2016 21
  • Products under Development by Companies, H2 2016 22
  • Products under Development by Companies, H2 2016 (Contd..1) 23
  • Products under Development by Companies, H2 2016 (Contd..2) 24
  • Products under Investigation by Universities/Institutes, H2 2016 25
  • Cancer Pain - Pipeline by Alexza Pharmaceuticals Inc, H2 2016 26
  • Cancer Pain - Pipeline by AngioChem Inc, H2 2016 27
  • Cancer Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2016 28
  • Cancer Pain - Pipeline by Aphios Corp, H2 2016 29
  • Cancer Pain - Pipeline by AstraZeneca Plc, H2 2016 30
  • Cancer Pain - Pipeline by Benitec Biopharma Ltd, H2 2016 31
  • Cancer Pain - Pipeline by BioDelivery Sciences International Inc, H2 2016 32
  • Cancer Pain - Pipeline by ChironWells GmbH, H2 2016 33
  • Cancer Pain - Pipeline by Colby Pharmaceutical Company, H2 2016 34
  • Cancer Pain - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 35
  • Cancer Pain - Pipeline by Dompe Farmaceutici SpA, H2 2016 36
  • Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corp, H2 2016 37
  • Cancer Pain - Pipeline by Grunenthal GmbH, H2 2016 38
  • Cancer Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016 39
  • Cancer Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2016 40
  • Cancer Pain - Pipeline by Immupharma Plc, H2 2016 41
  • Cancer Pain - Pipeline by IntelGenx Corp, H2 2016 42
  • Cancer Pain - Pipeline by iX Biopharma Ltd, H2 2016 43
  • Cancer Pain - Pipeline by Kancera AB, H2 2016 44
  • Cancer Pain - Pipeline by Klaria Pharma Holding AB, H2 2016 45
  • Cancer Pain - Pipeline by Komipharm International Co Ltd, H2 2016 46
  • Cancer Pain - Pipeline by KPI Therapeutics Inc, H2 2016 47
  • Cancer Pain - Pipeline by Neurocentrx Pharma Ltd, H2 2016 48
  • Cancer Pain - Pipeline by Nippon Kayaku Co Ltd, H2 2016 49
  • Cancer Pain - Pipeline by Orion Oyj, H2 2016 50
  • Cancer Pain - Pipeline by Pain Therapeutics Inc, H2 2016 51
  • Cancer Pain - Pipeline by Pfizer Inc, H2 2016 52
  • Cancer Pain - Pipeline by Pharmaleads SA, H2 2016 53
  • Cancer Pain - Pipeline by Recordati SpA, H2 2016 54
  • Cancer Pain - Pipeline by Ribomic Inc., H2 2016 55
  • Cancer Pain - Pipeline by Trillium Therapeutics Inc, H2 2016 56
  • Cancer Pain - Pipeline by Virobay Inc, H2 2016 57
  • Cancer Pain - Pipeline by WEX Pharmaceuticals Inc, H2 2016 58
  • Cancer Pain - Pipeline by Zynerba Pharmaceuticals Inc, H2 2016 59
  • Assessment by Monotherapy Products, H2 2016 60
  • Number of Products by Stage and Target, H2 2016 62
  • Number of Products by Stage and Mechanism of Action, H2 2016 65
  • Number of Products by Stage and Route of Administration, H2 2016 68
  • Number of Products by Stage and Molecule Type, H2 2016 70
  • Cancer Pain - Dormant Projects, H2 2016 141
  • Cancer Pain - Dormant Projects (Contd..1), H2 2016 142
  • Cancer Pain - Dormant Projects (Contd..2), H2 2016 143
  • Cancer Pain - Dormant Projects (Contd..3), H2 2016 144
  • Cancer Pain - Discontinued Products, H2 2016 145

List of Figures

  • Number of Products under Development for Cancer Pain, H2 2016 13
  • Number of Products under Development for Cancer Pain - Comparative Analysis, H2 2016 14
  • Number of Products under Development by Companies, H2 2016 15
  • Comparative Analysis by Late Stage Development, H2 2016 18
  • Comparative Analysis by Clinical Stage Development, H2 2016 19
  • Comparative Analysis by Early Stage Products, H2 2016 20
  • Assessment by Monotherapy Products, H2 2016 60
  • Number of Products by Top 10 Targets, H2 2016 61
  • Number of Products by Stage and Top 10 Targets, H2 2016 61
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 64
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 64
  • Number of Products by Top 10 Routes of Administration, H2 2016 67
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016 67
  • Number of Products by Top 10 Molecule Types, H2 2016 69
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016 69
Back to Top